Natural History Study of Retinitis Pigmentosa Type 11


Observational study of patients with retinitis pigmentosa type 11

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 1, 2023


  • Diagnostic Test: Clinical examinations
    • Clinical examinations

Clinical Trial Outcome Measures

Primary Measures

  • Progression of disease
    • Time Frame: 24 mounths
    • Retinal function measured by functional and structural testing

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of retinitis pigmentosa caused by a disease-causing mutation involving the PRPF31 gene – Or disease-causing mutation involving the PRPF31 gene without the clinical diagnosis of retinitis pigmentosa Exclusion Criteria:

  • Under 18 years – Other types of retinitis pigmentosa

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ragnheidur Bragadottir, Senior Consultant, Associate Professor – Oslo University Hospital
  • Overall Official(s)
    • Ragnheidur Bragadottir, MD, PHD, Principal Investigator, Department of Ophthalmology, Oslo University Hospital
  • Overall Contact(s)
    • Josephine P Holtan, MD, +22118589,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.